spacer
home > epc > autumn 2002 > in mergers - not the only way to grow
PUBLICATIONS
European Pharmaceutical Contractor

In Mergers - Not the Only Way to Grow

Contrary to the opinion of many industry analysts, the pharmaceutical industry is likely to see a slowdown in major merger and acquisition (M&A) activity in the near future. For growth, companies should look to other opportunities, such as more ambitious developments in the large, challenging markets of Japan, China and Brazil.

The Need for Action

The pharmaceutical industry has performed extremely well for many years, with high rates of profit and sales growth. The sector is very highly rated by investors and stock analysts. However, pressures which impact on revenues and profits are steadily growing for global pharmaceutical companies. For example, companies in the USA are suffering from problems of escalating sales and marketing costs. At the same time, they are facing product price pressures by insurers trying to contain private sector health costs. Europe is beset by R&D productivity problems, growing generic competition and the need to contain health costs in the public sector
(seeTable 1).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By John Morris, Head of KPMG's European Pharmaceutical Practic

John Morris is Head of KPMG's European Pharmaceutical Practice. Having graduated in chemistry, he joined KPMG and became a qualified Chartered Accountant, focusing on the chemicals and pharmaceuticals sectors.

John has been heavily involved in the international activities of the chemical and pharmaceutical industries, focusing mainly on issues related to mergers, acquisitions and divestments as the industries restructure and companies strive to improve performance.

spacer
John Morris
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sustainability, plastics and Brexit: Keynote speakers set to inspire at PPMA Total Show 2019

Experts from IKEA, the British Plastics Federation and The Sunday Times to create a forum for education, knowledge-sharing and debate
More info >>

White Papers

Future-proofing serialization solutions: the importance of strong level 3 capabilities

Adents

The complexities surrounding product serialization for pharmaceutical and medical device companies are immense. While current serialization requirements are limited to marking the unit of sale with a unique data carrier, by 2023 the process will require a product to be traceable through the entirety of its journey - from the individual package through the carton/pallet to its final point of distribution. In the United States, the Healthcare Distribution Management Association (HDMA) is suggesting that pharmaceutical companies begin to support this level of serialization, called aggregation, now. Around the world – in Europe and Asia in particular – disparate track and trace practices are incrementally moving toward a global standard that will, undoubtedly, be more stringent than today’s differing benchmarks. How can companies manage this transformation with the greatest degree of success while also minimizing business disruption? The key to creating an optimal implementation strategy is to select a serialization solution that has strong capabilities at all levels of technology. It’s also important to choose a solution that enables multi-phase implementation
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement